On the Path Towards Personalized Medicine: Implications of Pharmacogenetic Studies of Alcohol Use Disorder Medications

Overview

Journal Expert Rev Precis Med Drug Dev

Date 2021 Jul 22

PMID 34291172

Citations 1

Authors

Steven J Nieto

Erica N Grodin

Lara A Ray

Affiliations

Soon will be listed here.

Abstract

Introduction: The heritability of alcohol use disorder (AUD) is estimated to be ~50%; however, the genetic basis of the disease is still poorly understood. The genetic variants identified thus far only explain a small percentage of AUD phenotypic variability. While genome-wide association studies (GWAS) are impacted by technical and methodological limitations, genetic variants that have been identified independently of GWAS findings can moderate the efficacy of AUD medications.

Areas Covered: This review discusses findings from clinical pharmacogenetic studies of AUD medications. While the pharmacogenetic studies reviewed involve several genetic variants in the major neurotransmitter systems, genetic loci in the opioid system have garnered the most attention.

Expert Opinion: The clinical utility of pharmacogenetics in AUD populations is uncertain at this time. There are several ongoing prospective clinical trials that will enhance knowledge regarding the applicability of pharmacogenetics in clinical populations. We recommend that future work in this area consider reverse translating from genotype to phenotype, mapping genes to stages of the addiction cycle, mapping genes to neural circuits, and harnessing large population-based cohorts.

Citing Articles

Synchrony between midbrain gene transcription and dopamine terminal regulation is modulated by chronic alcohol drinking.

Farahbakhsh Z, Holleran K, Sens J, Fordahl S, Mauterer M, Lopez A Nat Commun. 2025; 16(1):1944.

PMID: 39994195 PMC: 11850823. DOI: 10.1038/s41467-025-56715-y.

Translational models of addiction phenotypes to advance addiction pharmacotherapy.

Ray L, Nieto S, Grodin E Ann N Y Acad Sci. 2022; 1519(1):118-128.

PMID: 36385614 PMC: 10823887. DOI: 10.1111/nyas.14929.

References

Ray L, Miranda Jr R, MacKillop J, McGeary J, Tidey J, Rohsenow D . A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp Clin Psychopharmacol. 2009; 17(2):122-9. PMC: 3682424. DOI: 10.1037/a0015700. View

Gelernter J, Kranzler H, Sherva R, Almasy L, Koesterer R, Smith A . Genome-wide association study of alcohol dependence:significant findings in African- and European-Americans including novel risk loci. Mol Psychiatry. 2013; 19(1):41-9. PMC: 4165335. DOI: 10.1038/mp.2013.145. View

Bauer L, Covault J, Harel O, Das S, Gelernter J, Anton R . Variation in GABRA2 predicts drinking behavior in project MATCH subjects. Alcohol Clin Exp Res. 2007; 31(11):1780-7. PMC: 3169387. DOI: 10.1111/j.1530-0277.2007.00517.x. View

Mann K, Roos C, Hoffmann S, Nakovics H, Lemenager T, Heinz A . Precision Medicine in Alcohol Dependence: A Controlled Trial Testing Pharmacotherapy Response Among Reward and Relief Drinking Phenotypes. Neuropsychopharmacology. 2017; 43(4):891-899. PMC: 5809801. DOI: 10.1038/npp.2017.282. View

Kranzler H, Zhou H, Kember R, Smith R, Justice A, Damrauer S . Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations. Nat Commun. 2019; 10(1):1499. PMC: 6445072. DOI: 10.1038/s41467-019-09480-8. View

Foroud T, Edenberg H, Goate A, Rice J, Flury L, Koller D . Alcoholism susceptibility loci: confirmation studies in a replicate sample and further mapping. Alcohol Clin Exp Res. 2000; 24(7):933-45. View

Richiardi J, Altmann A, Milazzo A, Chang C, Chakravarty M, Banaschewski T . BRAIN NETWORKS. Correlated gene expression supports synchronous activity in brain networks. Science. 2015; 348(6240):1241-4. PMC: 4829082. DOI: 10.1126/science.1255905. View

Schulze T, McMahon F . Defining the phenotype in human genetic studies: forward genetics and reverse phenotyping. Hum Hered. 2005; 58(3-4):131-8. DOI: 10.1159/000083539. View

Hart A, Kranzler H . Alcohol Dependence Genetics: Lessons Learned From Genome-Wide Association Studies (GWAS) and Post-GWAS Analyses. Alcohol Clin Exp Res. 2015; 39(8):1312-27. PMC: 4515198. DOI: 10.1111/acer.12792. View

10.

Ray L, Green R, Roche D, Bujarski S, Hartwell E, Lim A . Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial. Alcohol Clin Exp Res. 2017; 42(3):613-623. PMC: 6086578. DOI: 10.1111/acer.13586. View

11.

Lesch K, Bengel D, Heils A, Sabol S, Greenberg B, Petri S . Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996; 274(5292):1527-31. DOI: 10.1126/science.274.5292.1527. View

12.

Schuckit M . A Critical Review of Methods and Results in the Search for Genetic Contributors to Alcohol Sensitivity. Alcohol Clin Exp Res. 2018; 42(5):822-835. PMC: 5916326. DOI: 10.1111/acer.13628. View

13.

Edenberg H, Foroud T . The genetics of alcoholism: identifying specific genes through family studies. Addict Biol. 2006; 11(3-4):386-96. DOI: 10.1111/j.1369-1600.2006.00035.x. View

14.

Sahoo T, Theisen A, Rosenfeld J, Lamb A, Ravnan J, Schultz R . Copy number variants of schizophrenia susceptibility loci are associated with a spectrum of speech and developmental delays and behavior problems. Genet Med. 2011; 13(10):868-80. DOI: 10.1097/GIM.0b013e3182217a06. View

15.

Kendler K, Kalsi G, Holmans P, Sanders A, Aggen S, Dick D . Genomewide association analysis of symptoms of alcohol dependence in the molecular genetics of schizophrenia (MGS2) control sample. Alcohol Clin Exp Res. 2011; 35(5):963-75. PMC: 3083473. DOI: 10.1111/j.1530-0277.2010.01427.x. View

16.

Sanchez-Roige S, Fontanillas P, Elson S, Gray J, de Wit H, Davis L . Genome-wide association study of alcohol use disorder identification test (AUDIT) scores in 20 328 research participants of European ancestry. Addict Biol. 2017; 24(1):121-131. PMC: 6988186. DOI: 10.1111/adb.12574. View

17.

Skinner M, Lahmek P, Pham H, Aubin H . Disulfiram efficacy in the treatment of alcohol dependence: a meta-analysis. PLoS One. 2014; 9(2):e87366. PMC: 3919718. DOI: 10.1371/journal.pone.0087366. View

18.

Zuk O, Schaffner S, Samocha K, Do R, Hechter E, Kathiresan S . Searching for missing heritability: designing rare variant association studies. Proc Natl Acad Sci U S A. 2014; 111(4):E455-64. PMC: 3910587. DOI: 10.1073/pnas.1322563111. View

19.

Kranzler H, Armeli S, Tennen H . Post-treatment outcomes in a double-blind, randomized trial of sertraline for alcohol dependence. Alcohol Clin Exp Res. 2011; 36(4):739-44. PMC: 3721339. DOI: 10.1111/j.1530-0277.2011.01659.x. View

20.

Kreek M . Opiates, opioids and addiction. Mol Psychiatry. 1996; 1(3):232-54. View